Calprotectin is the best marker to discriminate between organic (IBD) and non-organic bowel disease (IBS). Calprotectin is a reliable indicator of inflammation in several pathologies. Patients suffering from IBS do not have increased faecal calprotectinvalues. Faecal calprotectin concentrations, as measured by the BÜHLMANN calprotectin assays, are significantly elevated in patients with IBD and correlate well with endoscopic and histological assessment of disease activity.
The biologic drug Infliximab is a therapeutic monoclonal antibody. It acts as is an antagonist to TNF alpha, thus is effective in blocking the inflammatory process in numerous chronic inflammatory diseases like Crohn’s disease, ulcerative colitis and inflammatory arthritis. The BÜHLMANN Quantum Blue® Infliximab is the first rapid test to measure infliximab trough level in patient’s serum to allow immediate decision making for potential drug dose adjustments.
The Quantum Blue® CRP test allows for a rapid determination of serum CRP within 15 minutes. It is an ideal tool to accompany the calprotectin determination for establishing an IBD patient inflammation profile during the course of the disease. The combination of the two markers has shown to increase the specificity for detecting inflammation in Crohn’s disease. The ease of use and speed of these two tests on the Quantum Blue® platform make this technology a very convenient addition to the therapy monitoring chronic inflammation of the gut.
MRP8/14 is an early and sensitive marker of inflammation and is released immediately in response to local inflammation. In contrast, other inflammatory markers are generated by downstream pathways and require de novo synthesis. Therefore, MRP8/14 is an ideal target for monitoring disease activity of Rheumatoid Arthritis. The MRP8/14 assays by BÜHLMANN allow for precise and sensitive measurement of this important marker.
The measurement of calprotectin in ascitic fluid provides reliable and rapid results using the Quantum Blue® technology. It provides a solution for point of care detection of spontaneous bacterial peritonitis, which is an important cause of morbidity and mortality in cirrhotic patients with ascites.